The days of traditional fire works are over! The Garucci family better wake up. The future is all about drones.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
The first stock lol......
The first one I ever made a killing off of was....
Where's Maria Bartiromo lol?
Who's her husband?
Its the cat that started WisdomTree. And all those funds.
But back in the late 80's he was unheard of.
He used to send out a newsletter of undiscovered stocks.
Snail mail. Pricey subscription too. I paid up for a year or two.
Anyway he found the company that had all the patents on caller ID.
When no one knew wtf caller ID was.
Caller ID Stoney!!!
I happened to be at someone's house shortly after that biweekly landed in my mailbox, and this dude was a "tech geek". He had it on his phone, it was this plug in console actually. When I saw our name on it.... I knew right then and there, caller id was gonna be huge. I bought the stock that Monday.
My first 2 bagger.
Had I held on... (story of my life)... it went way way higher. I think Lucent bought the whole thing.
Anyway....
I like drones Stoney.
I like em more if they shut China out.
He used to send out a newsletter of undiscovered stocks.
Snail mail. Pricey subscription too. I paid up for a year or two.
So did I send out a newsletter then--It was called Stoned Investing and it cost all of $10 an issue. Smith Barney and 1st Boston, Frank Q's office were my main delivery rout.
Snail mail. Pricey subscription too. I paid up for a year or two.
So did I send out a newsletter then--It was called Stoned Investing and it cost all of $10 an issue. Smith Barney and 1st Boston, Frank Q's office were my main delivery rout.
-I'M CLOSING MY EYES AND BUYING SNAP VAN!
LISTEN IT'S ON PAGE 1.......
LISTEN IT'S ON PAGE 1.......
NOW-IS-THE-TIME--
ATTENTION: IF YOU HAVE NOT BOUGHT SKILLZ YET -- NOW IS THE TIME!*** Warning warning***
ATTENTION: IF YOU HAVE NOT BOUGHT SKILLZ YET -- NOW IS THE TIME!*** Warning warning***
Last Call on Skillz....
--Skillz platform accelerates, Canacord initiates with Buy <-----
-- I own Gilliad in a different account The Hedge Fund Bought It for me actually against some of my protestations-- when they do that they usually have a good line on things... IRA types I would buy GILD.
--Veritone, Base Media Cloud announce six-year agreement
--Snap price target raised to $60 from $40 at KeyBanc
--Skillz platform accelerates, Canacord initiates with Buy <-----
-- I own Gilliad in a different account The Hedge Fund Bought It for me actually against some of my protestations-- when they do that they usually have a good line on things... IRA types I would buy GILD.
--Veritone, Base Media Cloud announce six-year agreement
--Snap price target raised to $60 from $40 at KeyBanc
I think we are going to have to be nimble with PINS-- I see both sides of this argument. But I see the short thesis pretty well... that being said it's ready to rumble...
This one is wacky-- Using Gold to cure MS??? Headline much!!
Clene Nanomedicine receives notice of allowance for use of gold nanocrystals 07:28 CLNN Clene announced that its wholly-owned subsidiary Clene Nanomedicine was issued a Notice of Allowance from the U.S. Patent and Trademark Office for its invention for using its patented clean-surfaced gold nanocrystals for treating patients with multiple sclerosis. Clene notes that its previously patented gold nanocrystals have surfaces that are substantially free from organic impurities and are therefore "clean" relative to surfaces of gold nanoparticles made by other processes. The allowed application discloses that these gold nanocrystals can be suspended in water and can be taken orally, for example, by a person with MS. New data is expected from Clene's REPAIR-MS Phase 2 study of CNM-Au8 in the second half of 2021. Prior interim results from this study showed CNM-Au8 was associated with improvements across key central nervous system bioenergetic metabolites. Clene's VISIONARY-MS Phase 2 study is evaluating the efficacy and safety of CNM-Au8 as a remyelinating and neuro-reparative treatment in stable relapsing MS patients with chronic visual impairment. Interim data from the Phase 2 VISIONARY-MS trial demonstrated notable, exposure-related median improvements in the primary endpoint. Completion of enrollment is expected by the end of 2021. Clene's worldwide patent portfolio in the new field of clean-surfaced nanocrystal therapeutics includes over 100 patents issued and allowed, with around 30 more pending. The issued patents cover state of matter claims for suspensions and solutions, as well as processes for making the materials, devices for conducting the unique electro-crystal chemistry processes, and methods of using the novel materials, such as in this instance of using clean-surfaced gold nanocrystals for treating patients with MS.
This one is wacky-- Using Gold to cure MS??? Headline much!!
Clene Nanomedicine receives notice of allowance for use of gold nanocrystals 07:28 CLNN Clene announced that its wholly-owned subsidiary Clene Nanomedicine was issued a Notice of Allowance from the U.S. Patent and Trademark Office for its invention for using its patented clean-surfaced gold nanocrystals for treating patients with multiple sclerosis. Clene notes that its previously patented gold nanocrystals have surfaces that are substantially free from organic impurities and are therefore "clean" relative to surfaces of gold nanoparticles made by other processes. The allowed application discloses that these gold nanocrystals can be suspended in water and can be taken orally, for example, by a person with MS. New data is expected from Clene's REPAIR-MS Phase 2 study of CNM-Au8 in the second half of 2021. Prior interim results from this study showed CNM-Au8 was associated with improvements across key central nervous system bioenergetic metabolites. Clene's VISIONARY-MS Phase 2 study is evaluating the efficacy and safety of CNM-Au8 as a remyelinating and neuro-reparative treatment in stable relapsing MS patients with chronic visual impairment. Interim data from the Phase 2 VISIONARY-MS trial demonstrated notable, exposure-related median improvements in the primary endpoint. Completion of enrollment is expected by the end of 2021. Clene's worldwide patent portfolio in the new field of clean-surfaced nanocrystal therapeutics includes over 100 patents issued and allowed, with around 30 more pending. The issued patents cover state of matter claims for suspensions and solutions, as well as processes for making the materials, devices for conducting the unique electro-crystal chemistry processes, and methods of using the novel materials, such as in this instance of using clean-surfaced gold nanocrystals for treating patients with MS.
--Iceland Foods extends distribution partnership with XPO Logistics 07:13 XPO XPO Logistics has renewed its contract with frozen food retail leader Iceland Foods for warehousing and distribution services. XPO will implement a phased strategy to increase growth capacity for the British supermarket chain, with scalable initiatives for technology, labor optimization, fleet optimization and cost savings. The renewal extends XPO's partnership with Iceland to more than a decade.
--CytoSorb approved in Korea for all EU approved indications 07:13 CTSO, FMS CytoSorbents (CTSO) announces that the Korean Ministry of Food and Drug Safety, or KMFDS, has approved CytoSorb for all equivalent European Union approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery. Clare Kim, Managing Director of Fresenius Medical Care (FMS) Korea commented, "In Korea, the sepsis mortality rate and incidence have increased steadily and remains a major problem in critical care. Under these circumstances, we are pleased to introduce the cytokine adsorber, CytoSorb, to healthcare professionals and patients in Korea. Fresenius Medical Care Korea remains committed to having a positive impact on the care of severely ill patients with CytoSorb."
--CytoSorb approved in Korea for all EU approved indications 07:13 CTSO, FMS CytoSorbents (CTSO) announces that the Korean Ministry of Food and Drug Safety, or KMFDS, has approved CytoSorb for all equivalent European Union approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery. Clare Kim, Managing Director of Fresenius Medical Care (FMS) Korea commented, "In Korea, the sepsis mortality rate and incidence have increased steadily and remains a major problem in critical care. Under these circumstances, we are pleased to introduce the cytokine adsorber, CytoSorb, to healthcare professionals and patients in Korea. Fresenius Medical Care Korea remains committed to having a positive impact on the care of severely ill patients with CytoSorb."
--Taysha gets both rare pediatric disease and orphan drug designations for TSHA-10 07:12 TSHA Taysha Gene Therapies announced that it has received both rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration, FDA for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. "There are no approved therapies for epilepsy caused by SLC13A5 that address the underlying cause of this disease," said RA Session II, President, Founder and CEO of Taysha. "We are encouraged by the early evidence of TSHA-105's disease-modifying approach and believe these designations will help us potentially accelerate the development of this exciting program. We look forward to working with the FDA to make TSHA-105 available to patients as expeditiously as possible."
--Xpeng initiated with a Hold at Jefferies
--Li Auto initiated with a Buy at Jefferies 06:59 LI Jefferies analyst Alexious Lee initiated coverage of Li Auto with a Buy rating and $44.50 price target. Li One's EREV powertrain has proven a great success, which should allow it to turn operating cash flow positive and profitable earlier than peers, argues Lee. Lee projects Li's sales to grow 100% and 86% year-over-year in FY21 and FY22, respectively, both of which are ahead of consensus.
Hummmmmm
--Xpeng initiated with a Hold at Jefferies
--Li Auto initiated with a Buy at Jefferies 06:59 LI Jefferies analyst Alexious Lee initiated coverage of Li Auto with a Buy rating and $44.50 price target. Li One's EREV powertrain has proven a great success, which should allow it to turn operating cash flow positive and profitable earlier than peers, argues Lee. Lee projects Li's sales to grow 100% and 86% year-over-year in FY21 and FY22, respectively, both of which are ahead of consensus.
Hummmmmm